Acyclic Carbon To Carbon Unsaturation Patents (Class 514/720)
-
Publication number: 20130281411Abstract: Compositions are disclosed that contain an effective inflammatory-dermatological disease-treating or condition-treating active agent and a pharmaceutically-acceptable carrier or vehicle. Methods of using the compositions to treat a subject's skin are also disclosed.Type: ApplicationFiled: June 17, 2013Publication date: October 24, 2013Inventor: Bryan B. Fuller
-
Publication number: 20130267588Abstract: The invention relates to hydroxytyrosol ethers derived from fatty alcohols and phenolic compounds of olive oil and the salts, solvates and hydrates thereof, which have an affinity for type 1 cannabinoid receptors (CB1) and which can: prevent the oxidation of low-density lipoprotein (LDL); and modulate the actions regulated by said receptor, such as inducing satiety, controlling intake and reducing body fat.Type: ApplicationFiled: December 19, 2011Publication date: October 10, 2013Applicants: FUNDACIO IMIM, FUNDACION INSTITUTO MEDITERRANEO PARA EL AVANCE DE LA BIOTECNOLOGIA Y LA INVESTIGACION SANITARIA, CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICASInventors: Rafael De La Torre Fornell, Magin Farre Albaladejo, Maria Isabel Covas Planells, Montserrat Fito Colomer, Bruno Almeida Cotrim, Fernando Rodriguez De Fonseca, Juan Manuel Decara Del Olmo, Miguel Romero Cuevas, Jesus Joglar Tamargo, Pedro Clapes Saborit
-
Patent number: 8541397Abstract: The present invention relates to novel alkyne and alkene derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-1-phosphate receptors.Type: GrantFiled: February 5, 2013Date of Patent: September 24, 2013Assignee: Allergan, Inc.Inventors: Santosh C. Sinha, Smita Bhat, Evelyn Corpuz, Ken Chow, Wenkui K. Fang, Wha-Bin Im
-
Publication number: 20130245070Abstract: The present invention relates to a method for enhancing arginase activity in a damaged or injured cell. In other aspects, the invention provides a method for treating a disorder that can be treated by enhancing arginase activity in a human in need thereof, the method comprising administering to the human an effective amount of a compound that enhances arginase activity. Such disorders include ischemia, hypoxia, neurodegenerative disease or condition, stroke or trauma of the nervous system. In yet another aspect, the invention provides methods for promoting regeneration of a neural cell in a human in need thereof.Type: ApplicationFiled: March 9, 2012Publication date: September 19, 2013Applicant: THE RESEARCH FOUNDATION OF THE CITY UNIVERSITY OF NEW YORKInventors: Rajiv R. Ratan, Marie T. Filbin
-
Patent number: 8530512Abstract: The present invention provides compounds and methods of using of the compounds as anti-infective and anthelminitc agents. In a preferred embodiment, the present invention provides the following compound of Formula III: wherein: R1 is not H when R2 is H and R2 is not H when R1 is H, further wherein R1 is OH or CH(2n+1)O, wherein n is 1-10; R2 is OH or CH(2n+1)O, where n is 1-10; W is alkyl, phenyl, halophenyl, pyridyl, piperidyl, or a substituted or unsubstituted aryl group, including unsubstituted and substituted aromatic heterocycles; and L is an optional linker or linking group selected from O, S, NH, CF2, or CH2, and x=0 or 1, i.e., if x=0, no linking group is present and when x=0, W is not phenyl.Type: GrantFiled: December 20, 2010Date of Patent: September 10, 2013Inventors: Aaron P. Monte, M. Shahjahan Kabir, Marc A. Rott, William R. Schwan, James M. Cook, III, Jennifer A. Miskowski, Ranjit Verma, Leah Defoe
-
Patent number: 8524782Abstract: The present invention provides a scalable process for the preparation of stilbenes by (i) condensing 3,5-dialkylbenzyl phosphonates with 4?-O-tetrahydropyranyl benzaldehyde to get 3,5-alkyl-4?-O-tetrahydropyranyl Stilbene and (ii) deprotecting the obtained 3,5-Dialkyl-4?-O-tetrahydropyranylstilbene to yield stilbenes. The present invention also provides a novel intermediate 3,5-Dialkyl-4?-O-tetrahydropyranyl stilbene, which is a key intermediate for the synthesis of stilbenes such as Pterostilbene and Resveratrol. The present invention also provides characteristics of various solid forms of Pterostilbene, methods for their preparation, as well as dosage forms containing the same for administration to or consumption by humans.Type: GrantFiled: January 21, 2011Date of Patent: September 3, 2013Assignee: Laurus Labs Private LimitedInventors: Gottumukkala V. Subbaraju, Masna Mahesh, Hindupur R. Mohan, Thatipally Suresh, Igor Ivanisevic, Mark Andres, Kyle Stephens
-
Publication number: 20130217782Abstract: Disclosed is a novel sirtuin modulating composition comprising an orally bioavailable SIRT-1 enhancing compound 3,5-dimethoxy-3,4?-dihydroxystilbene represented by STR#I. Also disclosed is an anti-acne composition comprising 3,5-dimethoxy-3,4?-dihydroxystilbenes represented by STR#I. Further, a novel sirtuin modulating composition comprising an orally bioavailable SIRT-1 enhancing compound 2,3?,5?,6-tetrahydroxy-trans-stilbene represented by STR#II is also disclosed.Type: ApplicationFiled: March 20, 2013Publication date: August 22, 2013Inventors: Muhammed Majeed, Kalyanam Nagabhushanam, Jefferey Reinhardt, Samuel Manoharan Thomas, Krishnamani Jayaraman
-
Publication number: 20130217696Abstract: A method of treatment of erectile dysfunction (ED) comprises the step of administering fispemifene to a subject in need thereof in an amount effective to raise the subject's testosterone level. Fispemifene may be used in combination with a PDE-5 inhibitor in individuals who have failed to respond sufficiently to conventional ED treatment. Methods are also disclosed of treating ED by administering clomifene, enclomifene, ospemifene, toremifene and mixtures thereof in combination with a PDE-5 inhibitor.Type: ApplicationFiled: March 21, 2013Publication date: August 22, 2013Applicant: QuatRX Pharmaceuticals CompanyInventors: Robert L. Zerbe, Alexander Bridges, Risto Lammintausta, Rochelle Hanley, Stuart Dombey
-
Publication number: 20130210775Abstract: Provided is an agent for reducing odors of pyrazine derivatives based on an olfactory receptor antagonism. The agent for reducing odors of pyrazine derivatives includes at least one antagonist of olfactory receptor OR5K1 as an active ingredient.Type: ApplicationFiled: December 4, 2012Publication date: August 15, 2013Applicant: Kao CorporationInventor: Kao Corporation
-
Publication number: 20130178489Abstract: The present invention relates to a method for fungicidal and/or bactericidal treatment of plants or foodstuffs using one or more essential oil(s) that enable the treatment of strains resistant to synthetic fungicides and/or bactericides.Type: ApplicationFiled: October 4, 2011Publication date: July 11, 2013Applicant: XEDA INTERNATIONALInventor: Alberto Sardo
-
Patent number: 8470890Abstract: This invention relates to a method for enhancing the bioavailability of a therapeutically active compound of the formula (I) or a geometric isomer, a stereoisomer, a pharmaceutically acceptable salt, an ester thereof or a metabolite thereof, wherein said compound is administered orally to the individual in connection with the intake of food.Type: GrantFiled: July 6, 2012Date of Patent: June 25, 2013Assignee: Hormos Medical Ltd.Inventor: Anttila Markku
-
Patent number: 8470861Abstract: The present invention is a mitochondria-targeted antioxidant prodrug useful for the prevention or treatment of diseases or conditions associated with mitochondrial dysfunction resulting from changes in the mitochondrial redox environment. Antioxidant prodrugs of the invention are produced by modifying an antioxidant to a fatty acid so that the resulting prodrug is targeted to and activated by an enzyme of mitochondrial fatty acid beta-oxidation.Type: GrantFiled: January 27, 2010Date of Patent: June 25, 2013Assignee: University of RochesterInventors: Marion W. Anders, James L. Robotham, Shey-Shing Sheu, Paul Spencer Brookes, Jalil Shojaie, Leif Olson, Richard L. Parton
-
Publication number: 20130156835Abstract: The present invention relates to a composition comprising one or more active ingredients of plant origin, or their synthetic analogues or extract(s) of plant origin containing them, encapsulated by the lecithin in an aqueous solution.Type: ApplicationFiled: April 14, 2011Publication date: June 20, 2013Inventor: Alberto Sardo
-
Publication number: 20130156816Abstract: The invention features compositions, methods, and kits for the administration of an oxidatively transformed carotenoid, or a fractionated component thereof, for use in aquaculture.Type: ApplicationFiled: February 18, 2011Publication date: June 20, 2013Applicant: Chemaphor Inc.Inventors: Larry Arthur Stobbs, James Gary Nickerson, Clayton Paul Dick
-
Publication number: 20130150455Abstract: The present invention relates to a pharmaceutical composition for selectively treating mechanical allodynia, which provides eugenol or a pharmaceutically acceptable salt thereof at a concentration lower than that which would inhibit voltage-gated sodium channels (VGSCs), a pharmaceutical composition for blocking hyperpolarization-activated current (Ih), and a transdermal preparation for treating mechanical allodynia comprising the composition. Even though administered at a concentration lower than that which would inhibit VGSCs, the eugenol of the present invention inhibits Ih in a cAMP or G-protein coupled receptor (GPCR) independent manner, thereby selectively ameliorating mechanical allodynia. Therefore, when the eugenol of the present invention is formulated into a transdermal preparation to be provided at a concentration lower than that which would inhibit VGSCs, and directly applied to the wound lesion, it can be used as a pharmaceutical composition capable of selectively treating mechanical allodynia.Type: ApplicationFiled: June 12, 2012Publication date: June 13, 2013Applicant: SNU R&DB FOUNDATIONInventors: Seog Bae OH, Sung Jun JUNG, Ge Hoon CHUNG, Yong Ho KIM
-
Publication number: 20130150331Abstract: The present invention relates to novel alkyne and alkene derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-1-phosphate receptors.Type: ApplicationFiled: February 5, 2013Publication date: June 13, 2013Applicant: ALLERGAN, INC.Inventor: ALLERGAN, INC.
-
Patent number: 8455553Abstract: The invention provides compositions and methods for reducing one or more symptoms of an autoimmune disease, inflammatory disease, and/or transplant rejection, by the administration to a subject in need thereof a pharmaceutically effective amount of a purified compound of any one of Formulae A-E. The invention's methods are useful for the prevention, amelioration, and treatment of autoimmune disease, inflammatory disease, and/or transplant rejection.Type: GrantFiled: November 10, 2011Date of Patent: June 4, 2013Assignee: The Regents of the University of CaliforniaInventor: Michael David
-
Publication number: 20130136778Abstract: The present invention refers to the use of PTER, or any acceptable salt thereof, optionally in combination with QUER, or any acceptable salt thereof, for the manufacture of pharmaceutical compositions for preventing and/or treating skin diseases, damages or injuries. Those methods of prevention and/or treatment comprise the administration of an effective amount of a composition comprising PTER as active compound, or any acceptable salt thereof, optionally in combination with QUER, or any acceptable salt thereof, to the subject. The present invention also refers to the compositions, per se, comprising PTER as active compound, or any acceptable salt thereof, optionally in combination with QUER, or any acceptable slat thereof, characterized by being formulated in the form of liposomes, and to the method for preparing said liposome formulations.Type: ApplicationFiled: October 29, 2010Publication date: May 30, 2013Applicant: GREEN MOLECULAR, S.L.Inventors: Jose Maria Estrela Ariquel, Miguel A. Asensi Miralles
-
Publication number: 20130131185Abstract: The invention provides in part dialkoxybenzene compounds for controlling infestation by a Trichoplusia ni, and methods thereof. The compounds include a compound of Formula I: where R1 may be methyl, ethyl, propyl, n-butyl, isopentyl (3-methylbutyl) or allyl; R2 may be at positions 2, 3 or 4 and may be H, methyl, ethyl, propyl, n-butyl, isopentyl (3-methylbutyl) or allyl; and R3 may be optionally present at positions 2, 3 and 4, and is allyl; except that when R2 is at position 2, R3 if present is at position 3, and when R2 is at position 3, R3 if present is at to positions 2 or 4, and when R2 is at position 4, R3 if present is at position 2, and when R2 is at position 4 and R3, if present, has reacted with an OH group at position 1 in a Markovnikov sense, then R3 becomes R4, a dihydrofuran.Type: ApplicationFiled: January 4, 2013Publication date: May 23, 2013Applicants: THE UNIVERSITY OF BRITISH COLUMBIA, SIMON FRASER UNIVERSITYInventors: SIMON FRASER UNIVERSITY, THE UNIVERSITY OF BRITISH COLUMBIA
-
Publication number: 20130129821Abstract: The present invention is directed to compositions and methods of delivery of CoQ that is reduced in the presence of lipoic acid and, optionally a fatty acid and/or optionally in a monoterpene. The compositions that include the reduced CoQ can be formulated in soft gel capsules.Type: ApplicationFiled: December 31, 2012Publication date: May 23, 2013Applicant: Soft Gel Technologies, Inc.Inventor: Soft Gel Technologies, Inc.
-
Publication number: 20130079293Abstract: Isolated compounds from adelostemma gracillimum refined fractions and compositions containing the compounds are provided by the present invention. Adelostemma gracillimum refined fractions and the extraction process thereof are also provided by the present invention. The uses of the compounds and the adelostemma gracillimum refined fractions for inhibiting the activities of NMDA receptor or amyloid-beta peptide, for improving memory, and for treating neurodegenerative diseases, neuropathological conditions or epilepsy are further provided by the present invention.Type: ApplicationFiled: March 18, 2011Publication date: March 28, 2013Applicant: BIOTECHNOLOGY RESEARCH CORPORATION LIMITEDInventors: Nancy Yuk-yu Ip, Fanny Chui-Fun Ip, Shengjun Guo
-
Patent number: 8404663Abstract: The present invention relates to novel alkyne and alkene derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-1-phosphate receptors.Type: GrantFiled: November 28, 2011Date of Patent: March 26, 2013Assignee: Allergan, Inc.Inventors: Santosh C. Sinha, Smita S. Bhat, Evelyn G. Corpuz, Ken Chow, Wenkui K. Fang, Wha-Bin Im
-
Publication number: 20130072509Abstract: A pharmaceutical composition is provided comprising a therapeutically effective amount of pterostilbene, a therapeutically effective amount of a statin compound, and a pharmaceutically acceptable carrier. The embodiments of the pharmaceutical compositions can have lipid lowering properties, or alternatively can have properties that can treat oxidative stress, by decreasing inflammation or inflammatory processes contributing to neurodegenerative diseases. A method of lowering lipid levels in an individual is also provided, comprising administering to the individual in need of such treatment a pharmaceutical composition including a therapeutically effective amount of pterostilbene, a therapeutically effective amount of a statin compound, and a pharmaceutically acceptable carrier, wherein lipid levels are decreased.Type: ApplicationFiled: September 14, 2012Publication date: March 21, 2013Applicant: ChromaDex Inc.Inventor: Jeremy Bartos
-
Publication number: 20130045178Abstract: The invention provides in part dialkoxybenzene and eugenol compounds for controlling infestation by a Lymantria dispar, and methods thereof. The compounds include a compound of Formula I: where R1 may be methyl, ethyl, propyl, n-butyl, isopentyl (3-methylbutyl) or allyl; R2 may be at positions 2, 3 or 4 and may be H, methyl, ethyl, propyl, n-butyl, isopentyl (3-methylbutyl) or allyl; and R3 may be optionally present at positions 2, 3 and 4, and is allyl; with the provisos that when R2 is at position 2, R3 if present is at position 3, or when R2 is at position 3, R3 if present is at positions 2 or 4, or when R2 is at position 4, R3 if present is at position 2; or of Formula II: where R1 may be methyl, ethyl, propyl, n-butyl, isopentyl (3-methylbutyl) or allyl; or mixtures thereof.Type: ApplicationFiled: August 22, 2012Publication date: February 21, 2013Inventors: ERIKA PLETTNER, Yongmei Gong, Regine Gries
-
Publication number: 20130023663Abstract: The present invention relates to stilbene and quinine compounds related to combretastatin A-4 and their use as anticancer compounds and prodrugs. The compounds include those with an alkyl group on the double bond of cis- or trans-stilbenes, compounds with one or more (and preferably 2 or 3) alkyl group substituents on the stilbene A ring, compounds with an alkoxy group other than methoxy at position 3, 4, and/or 5 of the stilbene A ring, compounds (or prodrugs) in which BBOC amino acid esters are formed with the phenolic hydroxyl at the 3 -position of the B ring and compounds (or prodrugs) based on a benzoquinone B ring. The present invention further relates to the photochemical reactions of stilbene compounds, either the above compounds disclosed for the first time herein or compounds based on prior stilbenes.Type: ApplicationFiled: August 17, 2012Publication date: January 24, 2013Inventors: John Anthony Hadfield, Alan Thomson McGown, Stephen Patrick Mayalap, Edwar John Land, Ian Hamblett, Keira Gaukroger, Nicholas James Lawrence, Lucy Annette Hepworth, John Butler
-
Patent number: 8350093Abstract: Methylated curcumin-methoxystilbene hybrid molecules that have particular use in treating cancer.Type: GrantFiled: May 13, 2010Date of Patent: January 8, 2013Assignee: Codman & Shurtleff, Inc.Inventor: Thomas M. DiMauro
-
Publication number: 20120316227Abstract: Embodiments of antimicrobial chrysophaentin compounds, pharmaceutical compositions including the chrysophaentin compounds, and methods for using the chrysophaentin compounds are disclosed. Some embodiments of the disclosed compounds are isolated from Chrysophaeum taylori. Certain embodiments of the chrysophaentin compounds inhibit FtsZ protein, thereby inhibiting the growth of clinically relevant bacteria, including drug-resistant strains.Type: ApplicationFiled: February 25, 2011Publication date: December 13, 2012Inventors: Carole A. Bewley, Alberto Plaza, Jessica Keffer
-
Publication number: 20120288579Abstract: The present invention relates to a novel use of lignan compounds, which are isolated and purified from nutmeg or the aril of nutmeg for anti-wrinkle, and more particularly, the present invention relates to a novel use for anti-wrinkle of an extract of the nutmeg or an extract of the aril of the nutmeg, fragrin A, austobailignan 7, licarin E, and macelignan. The extracts and lignan compounds of the present invention have activities in suppressing collagen degradation enzyme-1 (MMP-1, matrix metalloprotei-nase-1) and formation of new collagen (type-1 procollagen), thereby having effect on inhibitng wrinkle caused by photoaging. Accordingly, the extracts and lignan compounds of the present invention may be useful for preventing or treating wrinkle caused by photoaging.Type: ApplicationFiled: June 20, 2009Publication date: November 15, 2012Applicant: BIOCARE CO. LTD.Inventors: Jae-Kwan Hwang, Hae Ji Lee, Jae Young Lee, Jae-Seok Shim, Jeong Hwan Kim, Do Un Kim, Heechul Chung, Jae Youn Chung
-
Publication number: 20120289605Abstract: A method is provided for treating an individual for a cellular proliferative disorder, including administering to the individual in need of such treatment a therapeutically effective amount of the compound pterostilbene wherein UDP-glucuronosyltransferase (UGT) activity is increased. In an embodiment, 12-HETE levels can be reduced by administration of pterostilbene.Type: ApplicationFiled: May 8, 2012Publication date: November 15, 2012Applicants: The Regents of the University of California, ChromaDex Inc.Inventors: Jeremy Bartos, Ryan Dellinger
-
Publication number: 20120276022Abstract: The present invention relates to a method of disinfecting a surface and to antimicrobial composition, particularly for personal cleaning, oral care, or hard surface cleaning. It is an object of the present invention to provide for an antimicrobial composition that has relatively fast antimicrobial action. The inventors have found that use of small amounts of eugenol in combination with thymol and terpineol enables this fast kinetics at much lower amount of thymol and terpineol than without eugenol.Type: ApplicationFiled: September 3, 2010Publication date: November 1, 2012Inventors: Srilaxmi Venkata Medepalli, Amit Chakrabortty, Bharat Cheviti
-
Publication number: 20120277169Abstract: Estrogenic compositions comprising nyasol and analogs thereof are provided. Also provided are methods of using said extracts to achieve an estrogenic effect, especially in a human, e.g. a female human. In some embodiments, the methods include treatment of climacteric symptoms. In some embodiments, the methods include treatment of estrogen receptor positive cancer, such as estrogen responsive breast cancer. In some embodiments, the methods include treatment or prevention of osteoporosis.Type: ApplicationFiled: November 1, 2011Publication date: November 1, 2012Applicant: BioNovo, Inc.Inventor: Isaac Cohen
-
Publication number: 20120270952Abstract: This invention relates to a method for enhancing the bioavailability of a therapeutically active compound of the formula (I) or a geometric isomer, a stereoisomer, a pharmaceutically acceptable salt, an ester thereof or a metabolite thereof, wherein said compound is administered orally to the individual in connection with the intake of food.Type: ApplicationFiled: July 6, 2012Publication date: October 25, 2012Applicant: Hormos Medical CorporationInventor: Markku ANTTILA
-
Publication number: 20120225109Abstract: A formulation to reduce the numbers of bacteria, particularly Gram positive bacteria, in a space such as a waste disposal bin, via the vapor phase, and active over a long period, typically several weeks. The product comprises one or more essential oils or essential oil components plus a mixture of volatile and non-volatile solvents, on a carrier such as a non-woven, sintered plastic or cardboard.Type: ApplicationFiled: March 9, 2012Publication date: September 6, 2012Inventors: Philip Caunt, Deborah Williams
-
Publication number: 20120220554Abstract: Methods and compositions for the treatment and prevention of posterior capsular opacification are provided. The method comprises administering a therapeutically effective amount of a combretastatin to a subject suffering from or at risk of developing posterior capsule opacification.Type: ApplicationFiled: January 2, 2012Publication date: August 30, 2012Applicant: OXIGENE, INC.Inventors: Roy Quinlan, Frederique Tholozan
-
Patent number: 8252845Abstract: Resveratrol has been reported to have hypolipidemic properties. We investigated whether resveratrol and its analogs: pterostilbene, piceatannol and resveratrol trimethyl ether, would activate the peroxisome proliferator-activated receptor alpha (PPAR?) isoform. This nuclear receptor is proposed to mediate the activity of lipid-lowering drugs such as the fibrates. The four stilbenes and ciprofibrate (positive control) were evaluated for the activation of endogenous PPAR? in H4IIEC3 cells transfected with a luciferase gene reporter construct. Pterostilbene demonstrated the highest induction of PPAR?; the maximal response to pterostilbene was similar to that obtained with the hypolipidemic drug, ciprofibrate.Type: GrantFiled: February 1, 2012Date of Patent: August 28, 2012Assignees: The United States of America, as represented by the Secretary of Agriculture, The University of MississippiInventors: Agnes M. Rimando, Dennis R. Feller, Wallace H. Yokoyama
-
Publication number: 20120208874Abstract: A composition comprising an alkynyl phenoxy compound of Formula (I) as a synergist and a pesticidal active ingredient is described, wherein R1 and R2, similar or different, are (C1-C4)alkyl or R1O— and R2O— together represent a group —O—CH2—O—, —O—CH(CH3)—O, —O—CH2—CH2—O—, —O—CH2—CH2—, R3 is (C1-C6)alkyl, (C3-C6)alkenyl or —B—(CH2-CH2—O)z-R6 where B is —CH2—O— or —O—, z is 0, 1 or 2 and R6 is (C1-C4)alkyl; R4 is hydrogen or methyl; R5 is hydrogen or methyl; x is an integer from 1 to 2; y is 0, 1 or 2; with the proviso that when R3 is —B—(CH2CH2—O)z-R6, y is 1 and 5-(propargyloxy)-benzo[1,3]dioxole is excluded.Type: ApplicationFiled: August 18, 2010Publication date: August 16, 2012Inventors: Valerio Borzatta, Elisa Capparella, Leni Moroni, Graham Moores, Despina Philippou
-
Patent number: 8236861Abstract: This invention relates to a method for enhancing the bioavailability of a therapeutically active compound of the formula (I) or a geometric isomer, a stereoisomer, a pharmaceutically acceptable salt, an ester thereof or a metabolite thereof, wherein said compound is administered orally to the individual in connection with the intake of food.Type: GrantFiled: February 13, 2004Date of Patent: August 7, 2012Assignee: Hormos Medical CorporationInventor: Markku Anttila
-
Publication number: 20120196874Abstract: Stilbene analogs and pharmaceutical compositions that are useful for the treatment of various cancers, including without limitation, colorectal cancer (CRC) and breast cancer are disclosed. The halogenated stilbene analogs include nitrogen heteroaryl groups and/or amino groups on the stilbene ring.Type: ApplicationFiled: January 27, 2012Publication date: August 2, 2012Inventors: David WATT, Chunming Liu, Vitaliy M. Sviripa, Wen Zhang
-
Publication number: 20120178704Abstract: Stilbene compounds for the prevention and treatment of colon cancer or colon inflammation and methods of using same are provided.Type: ApplicationFiled: December 7, 2007Publication date: July 12, 2012Inventors: Agnes M. Rimando, Nanjoo Suh, Cassia Mizuno, Bandaru s. Reddy, Sada L. Reddy
-
Publication number: 20120142640Abstract: The present invention relates to novel alkyne and alkene derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-1-phosphate receptors.Type: ApplicationFiled: November 28, 2011Publication date: June 7, 2012Applicant: ALLERGAN, INC.Inventors: Santosh C. Sinha, Smita S. Bhat, Evelyn G. Corpuz, Ken Chow, Wenkui K. Fang, Wha-Bin Im
-
Publication number: 20120135971Abstract: The present invention relates to methods and compositions for treating a subject suffering from a sclerosing disorder, comprising administering, to the subject, an effective amount of an estrogen receptor antagonist (“ERANT”), wherein said ERANT has essentially no estrogen receptor agonist activity under physiologic conditions.Type: ApplicationFiled: January 18, 2012Publication date: May 31, 2012Inventors: Carol A. Feghali-Bostwick, Pamela Anne Hershberger
-
Publication number: 20120135091Abstract: The present invention concerns the use of active compounds, including chalcogenides and sirtuin-modulating compounds, either alone or in combination for increasing or enhancing survivability and/or longevity in biological matter. In general aspects, the chalcogenides and other active compounds may modulate one or more sirtuin proteins. It includes compositions, methods, articles of manufacture and apparatuses for enhancing survivability in any of these biological materials, so as to preserve and/or protect them. In specific embodiments, there are also therapeutic methods and apparatuses for aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, organ transplantation, hyperthermia, wound healing, hemorrhagic shock, cardioplegia for bypass surgery, neurodegeneration, hypothermia, and cancer using the active compounds described.Type: ApplicationFiled: January 18, 2008Publication date: May 31, 2012Inventors: Mark B. Roth, Dana L. Miller
-
Publication number: 20120122995Abstract: An anti-inflammatory agent or cancer-preventive agent comprising 4-vinyl-2,6-dimethoxyphenol of the formula (1): or a PD thereof.Type: ApplicationFiled: January 20, 2012Publication date: May 17, 2012Inventors: Hiroshi Maeda, Tetsuya Tsukamoto, Masae Tatematsu
-
Publication number: 20120107428Abstract: Provided herein are essential oils and synthetic compounds, and combinations thereof, as repellent compositions for repelling insects, such as vespid social wasps (Vespidae), including yellowjackets, paper wasps, and hornets. Controlled release devices comprising these repellent compositions are also provided.Type: ApplicationFiled: August 9, 2011Publication date: May 3, 2012Applicant: Sterling International Inc.Inventors: Rodney G. Schneidmiller, Qing-He Zhang, Doreen R. Hoover
-
Publication number: 20120107415Abstract: The invention relates to a novel combined disinfection and decontamination agent comprising at least one vitamin, at least one metal ion, at least one active-surface compound, and at least one further antimicrobial active substance. The agent according to the invention surprisingly shows nearly complete nucleic acid disintegration in addition to an improved disinfectant effect. The agent can be successfully used as a combined decontamination and disinfection agent for skin, mucous membranes, hands, wounds, and/or hair, and instruments and surfaces of all kinds.Type: ApplicationFiled: November 14, 2009Publication date: May 3, 2012Inventors: Thomas Lisowsky, Sven Eggerstedt, Richard Bloss, Christiane Ostermeyer, Karlheinz Esser, Frank Bürger, Barbara Krug, Yvonne Feil, Kai-Martin Mueller, Delphine Haase
-
Publication number: 20120087964Abstract: The present disclosure relates to water dispersible granular pesticide compositions, and methods of making and using the compositions. The pesticide compositions include an inner layer including a first pesticide coated on to a substrate, and an outer layer comprising a second pesticide coated on the inner layer. The outer layer increases the water dispersibility of the granular composition, and protects the first pesticide against hydrolysis and photolysis.Type: ApplicationFiled: October 12, 2011Publication date: April 12, 2012Applicant: ECOLAB USA INC.Inventors: Victor F. Man, Yvonne M. Killeen, Susan M. Viall
-
Publication number: 20120087913Abstract: Methods and compositions for enhancing the ability of hypoxia-activated bioreductive agents to kill tumor cells within solid tumors are provided. Local regions of hypoxia are created within a tumor, or within a region containing a tumor, resulting in enhanced activation of hypoxia-activated bioreductive agents (e.g. tirapazamine) within the local region. The activated hypoxia-activated bioreductive agents kill tumor cells in the hypoxic region by catalyzing DNA stand breakage within the tumor cells. Because the activity is localized, side effects that typically occur as a result of systemic administration of bioreductive agents are reduced.Type: ApplicationFiled: April 8, 2009Publication date: April 12, 2012Inventors: Ruey-min Lee, Peck-sun Lee
-
Publication number: 20120087871Abstract: Methods for killing insects and a nest are disclosed. The methods may be used to disrupt a colony of nestdwelling insects. The insects may include wasps, hornets, and yellowjackets.Type: ApplicationFiled: September 30, 2011Publication date: April 12, 2012Applicant: STERLING INTERNATIONAL INC.Inventors: Rodney G. Schneidmiller, Qing-He Zhang, Guiji Zhou, Doreen R. Hoover
-
Publication number: 20120071561Abstract: The invention provides compositions and methods for reducing one or more symptoms of an autoimmune disease, inflammatory disease, and/or transplant rejection, by the administration to a subject in need thereof a pharmaceutically effective amount of a purified compound of any one of Formulae A-E. The invention's methods are useful for the prevention, amelioration, and treatment of autoimmune disease, inflammatory disease, and/or transplant rejection.Type: ApplicationFiled: November 10, 2011Publication date: March 22, 2012Inventor: Michael DAVID
-
Patent number: 8133917Abstract: Resveratrol, a stilbenoid antioxidant found in grapes, wine, peanuts and other berries, has been reported to have hypolipidemic properties. Resveratrol and its three analogs (pterostilbene, piceatannol and resveratrol trimethyl ether) were evaluated for their effects on the activation of the peroxisome proliferator-activated receptor alpha (PPAR?) isoforms, a receptor shown to mediate the activity of lipid-lowering drugs such as the fibrates. The four stilbenes and ciprofibrate (positive control) were evaluated for the activation of endogenous PPAR? in H4IIEC3 cells. Pterostilbene demonstrated the highest induction of PPAR? demonstrating increases of 7- and 9-14 fold relative to control. The maximal responses to pterostilbene are similar to those obtained with the hypolipidemic drug, ciprofibrate; that is, pterostilbene acts as a PPAR? agonist, like that of the fibrate class, and is a more effective hypolipidemic agent than resveratrol.Type: GrantFiled: October 25, 2010Date of Patent: March 13, 2012Assignees: The United States of America as represented by the Secretary of Agriculture, The University of MississippiInventors: Agnes M. Rimando, Dennis R. Feller, Wallace H. Yokoyama